American Society of Hirudotherapy

Diabetic Peripheral Neuropathy (Investigational Adjunct)

Investigational adjunct for symptomatic diabetic peripheral neuropathy; glycemic control, foot care, and pharmacotherapy (duloxetine, pregabalin, gabapentin) remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for diabetic peripheral neuropathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational and is generally inadvisable because the risk profile in diabetic patients is uniquely unfavorable.
What evidence exists?
Tier C (investigational). Leech therapy has been tested in one small randomized trial from Iran (40 patients, compared with low-dose gabapentin) and one Russian non-randomized study in diabetic-foot patients; both reported better neuropathy scores, but both are small and cannot establish long-term safety in people with diabetes. The only intervention with disease-modifying evidence is tight glycemic control (HbA1c target individualized). Symptom control is evidence-based: duloxetine, pregabalin, gabapentin, amitriptyline, and topical capsaicin or lidocaine - all with RCT support. Foot care (daily inspection, well-fitting footwear, podiatry follow-up, monofilament screening) is critical to prevent ulcer and amputation. Diabetic patients have impaired healing and high infection risk, which makes any skin-breaking procedure - including leech bites - dangerous.
Main risks
  • Bleeding from the bite site for 6 to 24 hours after detachment
  • Slow or non-healing of the bite wound in diabetic skin
  • HIGH RISK of skin or, in particular, Aeromonas hydrophila infection - serious in diabetes
  • Risk of triggering a non-healing diabetic ulcer at the bite site
  • Cellulitis, deep tissue infection, or osteomyelitis from a contaminated bite
  • Risk of progression to limb-threatening infection (especially in patients with peripheral arterial disease)
  • Allergic reaction to leech saliva (uncommon)
  • Delay of evidence-based glycemic optimization and pharmacotherapy
Who should not consider this
  • Patients with any active diabetic foot ulcer, cellulitis, or osteomyelitis
  • Patients with peripheral arterial disease (ABI under 0.7) or absent pedal pulses
  • Patients with poorly controlled diabetes (HbA1c above 8.5 percent)
  • Patients with reduced protective sensation on monofilament testing (cannot reliably detect bite-site complications)
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients with active retinopathy who cannot afford additional anemia risk
  • Patients with end-stage renal disease or significant immunosuppression
What to ask your clinician
  • What is my HbA1c, and have we optimized glycemic control first?
  • Have I had a foot exam, monofilament testing, and ABI to assess for peripheral arterial disease?
  • Have I tried evidence-based pharmacotherapy (duloxetine, pregabalin, gabapentin, amitriptyline)?
  • Have I tried topical capsaicin or lidocaine patches?
  • Why is leech therapy being considered given the high infection and non-healing risk in diabetes?
  • What is the Aeromonas-prevention protocol, and what is the fallback if infection develops?
  • Where exactly will leeches be placed - confirm NEVER on the foot, NEVER over an area with reduced sensation?
When to seek urgent care
  • Any non-healing wound, ulcer, or persistent open bite site
  • Spreading redness, warmth, drainage, or pus at the bite site or anywhere on the foot
  • Fever, chills, or sudden worsening of glycemic control (possible deep infection)
  • Sudden severe foot pain, pallor, or coolness (possible critical limb ischemia)
  • Red streaks running up the leg from the bite site (lymphangitis)
  • Bleeding from the bite site lasting more than 24 hours
  • Hives, facial or throat swelling, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for diabetic peripheral neuropathy.
  • It has not been shown to improve glycemic control, which can prevent DPN in type 1 diabetes and may modestly slow its progression in type 2 (ADA Standards of Care).
  • It does not replace duloxetine, pregabalin, or gabapentin for neuropathic pain - these have RCT support.
  • It is uniquely dangerous in diabetic patients: bleeding from a bite plus impaired healing plus high infection risk can precipitate ulcer or limb loss.
  • Most clinicians should decline; the risk-benefit ratio is unfavorable.

Clinical Profile

Category
Neurological
ICD-10
E11.40, E11.42, G62.9, G99.0
Safety tier
High

Evidence Summary

Diabetic peripheral neuropathy (DPN) is the most common diabetic microvascular complication, causing distal symmetric sensory loss and neuropathic pain. ADA evidence-based management includes optimal glycemic control, foot care education, screening, and pharmacotherapy with duloxetine, pregabalin, gabapentin, or amitriptyline for painful neuropathy. Topical capsaicin and lidocaine play adjunctive roles. Hirudotherapy for DPN has been tested in one small randomized trial from Iran (Alemi 2022: 40 patients given leech therapy or gabapentin 300 mg daily, patients unblinded, 45-day follow-up), which reported greater improvement in neuropathy symptom and disability scores with leeches, and in a Russian non-randomized comparison in diabetic-foot patients with neuropathy (Leontiev 2007, 97 patients; thesis 2009, 147 patients), which reported better vibration and thermal sensation tests with leech therapy plus the leech-derived drug Piyavit. Both are small, from single regions and not replicated as far as we found, and no large blinded trial was identified (search of October 2026). Diabetic patients have heightened infection risk, impaired wound healing, and are often anticoagulated for cardiovascular indications, making the risk-benefit profile especially unfavorable. Distal foot placement is dangerous in this population because of compromised microcirculation and ulcer risk.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Active diabetic foot ulcer or callus breakdown
  • Charcot foot or active osteomyelitis
  • HbA1c >8 percent (optimize glycemic control first)
  • Distal foot placement (always contraindicated in DPN)
  • Peripheral arterial disease with ABI <0.9

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.